Researchers at Servizo Galego de Saude and Universidade de Santiago de Compostela have described senolytic compounds reported to be useful for the treatment of cancer, metabolic diseases, and neurological, dermatological, cardiovascular, eye, renal and inflammatory disorders.

Incurix Co. Ltd. has identified Myc proto-oncogene protein (c-Myc) inhibitors reported to be useful for the treatment of cancer.

Merck KGaA has synthesized transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) and/or TAZ/TEAD interaction inhibitors reported to be useful for the treatment of cancer.